Summary
26.44 0.13(0.49%)09/13/2024
Exelixis Inc (EXEL)
Exelixis Inc (EXEL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.48 | 5.07 | -0.94 | 20.32 | 14.48 | 19.31 | 37.42 | 79.25 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 26.44 | |
| Open | 26.34 | |
| High | 26.50 | |
| Low | 26.19 | |
| Volume | 685,834 | |
| Change | 0.13 | |
| Change % | 0.48 | |
| Avg Volume (20 Days) | 998,855 | |
| Volume/Avg Volume (20 Days) Ratio | 0.69 | |
| 52 Week Range | 18.64 - 27.53 | |
| Price vs 52 Week High | -3.96% | |
| Price vs 52 Week Low | 41.85% | |
| Range | 0.39 | |
| Gap Up/Down | -0.29 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,548 | |
| EBIDTA | 229,592,000 | |
| PE Ratio | 32.8769 | |
| PEG Ratio | 1.6856 | |
| WallStreet Target Price | 26.74 | |
| Book Value | 7.2130 | |
| Earnings Per Share | 0.6500 | |
| EPS Estimate Current Quarter | 0.2400 | |
| EPS Estimate Next Quarter | 0.3100 | |
| EPS Estimate Current Year | 1.1300 | |
| EPS Estimate Next Year | 1.4900 | |
| Diluted EPS (TTM) | 0.6500 | |
| Revenues | ||
| Profit Marging | 0.1110 | |
| Operating Marging (TTM) | 0.1465 | |
| Return on asset (TTM) | 0.0430 | |
| Return on equity (TTM) | 0.0876 | |
| Revenue TTM | 1,846,646,016 | |
| Revenue per share TTM | 5.9140 | |
| Quarterly Revenue Growth (YOY) | 0.0400 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,553,153,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 32.8769 | |
| Forward PE | 17.6678 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.0548 | |
| Revenue Enterprise Value | 3.3387 | |
| EBITDA Enterprise Value | 31.0806 | |
| Shares | ||
| Shares Outstanding | 291,292,992 | |
| Shares Float | 254,817,032 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 2.23 | |
| Institutions (%) | 90.85 | |
09/02 10:51 EST - zacks.com
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
08/29 12:40 EST - zacks.com
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
08/29 10:41 EST - zacks.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
08/29 10:01 EST - zacks.com
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.
08/28 16:05 EST - businesswire.com
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 9:15 a.m. ET / 6:15 a.m. PT on Wednesday, September 4 in New York City. 2024 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 10:15 a.m. ET / 7:15 a.m. PT on Friday, September 6 in Everett, MA.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 9:15 a.m. ET / 6:15 a.m. PT on Wednesday, September 4 in New York City. 2024 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 10:15 a.m. ET / 7:15 a.m. PT on Friday, September 6 in Everett, MA.
08/26 13:20 EST - zacks.com
Why Exelixis (EXEL) Might be Well Poised for a Surge
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Why Exelixis (EXEL) Might be Well Poised for a Surge
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
08/16 08:09 EST - fxempire.com
Exelixis Earnings Drive Share Growth
Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.
Exelixis Earnings Drive Share Growth
Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.
08/15 10:35 EST - marketbeat.com
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve's monetary policy regarding interest rates is neither too restrictive nor too loose.
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve's monetary policy regarding interest rates is neither too restrictive nor too loose.
08/13 12:45 EST - seekingalpha.com
4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)
Investors are seeking stability amid the global market selloff in early August, sparked by weak jobs data and fears of an emergency interest rate cut by the Fed. Recession fears were ignited after the yield curve uninverted to cause speculation that the Fed could begin rate cuts in September. With many investors on the defense, and seeking safe-haven investments, staples, healthcare, and utilities have outperformed the market during six of the last seven U.S. recessions.
4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)
Investors are seeking stability amid the global market selloff in early August, sparked by weak jobs data and fears of an emergency interest rate cut by the Fed. Recession fears were ignited after the yield curve uninverted to cause speculation that the Fed could begin rate cuts in September. With many investors on the defense, and seeking safe-haven investments, staples, healthcare, and utilities have outperformed the market during six of the last seven U.S. recessions.
08/13 12:40 EST - zacks.com
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
08/13 10:45 EST - zacks.com
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
08/12 10:21 EST - zacks.com
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
08/08 16:04 EST - seekingalpha.com
Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost
Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product revenues of Cabometyx grew by 16% quarter over quarter and a 7% year-over-year increase. Preliminary results from phase 3 STELLAR-303 study, using zanzalintinib in combination with Tecentriq to treat patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient.
Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost
Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product revenues of Cabometyx grew by 16% quarter over quarter and a 7% year-over-year increase. Preliminary results from phase 3 STELLAR-303 study, using zanzalintinib in combination with Tecentriq to treat patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient.
08/07 14:58 EST - businesswire.com
Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impact
LEMONT, Ill.--(BUSINESS WIRE)--The tool — free to all users — estimates energy consumption for a wide range of vehicles, both current and future.
Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impact
LEMONT, Ill.--(BUSINESS WIRE)--The tool — free to all users — estimates energy consumption for a wide range of vehicles, both current and future.
08/07 14:30 EST - zacks.com
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
08/07 14:15 EST - benzinga.com
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed.
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed.
08/06 21:30 EST - seekingalpha.com
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - Executive Vice President of Commercial Conference Call Participants Asthika Goonewardene - Truist Jay Olson - Oppenheimer Joyce Zhou - TD Cowen Andy Hsieh - William Blair Silvan Tuerkcan - Citizens JMP David Lebowitz - Citi Michael Riad - Morgan Stanley Jason Gerberry - Bank of America Akash Tewari - Jefferies Alex Bullocks - Barclays Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Operator Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2024 Financial Results Conference Call.
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - Executive Vice President of Commercial Conference Call Participants Asthika Goonewardene - Truist Jay Olson - Oppenheimer Joyce Zhou - TD Cowen Andy Hsieh - William Blair Silvan Tuerkcan - Citizens JMP David Lebowitz - Citi Michael Riad - Morgan Stanley Jason Gerberry - Bank of America Akash Tewari - Jefferies Alex Bullocks - Barclays Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Operator Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2024 Financial Results Conference Call.
08/06 19:36 EST - zacks.com
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
08/06 18:37 EST - zacks.com
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago.
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago.
08/05 10:21 EST - zacks.com
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.